EGFR and non-small cell lung carcinoma: In non-small cell lung cancer (NSCLC), EGFR exon 19 deletion and L858R mutations are predictive biomarkers for EGFR tyrosine kinase inhibitor (TKI) efficacy; both markers are associated with significantly longer progression-free survival (PFS)1–5.